Results 131 to 140 of about 165,018 (302)

Membrane‐Active Peptide Protects Against Inflammation by Targeting NLRP3 Activation at the Trans‐Golgi Network

open access: yesAdvanced Science, EarlyView.
The membrane‐active peptide Pep19‐2.5 reduces harmful inflammation by blocking activation of the NLRP3 inflammasome at trans‐Golgi network membranes. By targeting key membrane interactions, Pep19‐2.5 suppresses inflammatory IL‐1β production and alleviates allergic airway inflammation in mice, leading to reduced immune cell infiltration and improved ...
Jonas Engelhardt   +16 more
wiley   +1 more source

PEAR1 Promotes Glucose Metabolism Reprogramming in Sepsis‐Associated Acute Lung Injury via AARS1‐Mediated HIF‐1α Lactylation

open access: yesAdvanced Science, EarlyView.
This study revealed that a PEAR1/HIF‐1α/ glycolysis/lactate/H3K18la positive feedback loop in PMVECs that drives the development of S‐ALI. Mechanistically, PEAR1 mediates the binding of HIF‐1α to AARS1, leading to the lactylation of HIF‐1α, the primary lactylation site of which is K172.
Shuai Li   +15 more
wiley   +1 more source

Spatiotemporally Ultrasound‐Controlled Nanoparticles Reprogramming Immunostimulatory Antigen‐Presenting Cancer‐Associated Fibroblasts to Enhance Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
We developed an ultrasound‐controlled biomimetic nanoplatform, mRNA/V@M NPs, to co‐deliver CD74 mRNA and V‐9302 for fibrotic TNBC therapy. CD74 mRNA reprograms myCAFs into antigen‐presenting apCAF cells through the CD74‐MHC II pathway, while V‐9302 induces ICD and activates MHC I‐CD8+ T cell immunity.
Chen Ai   +9 more
wiley   +1 more source

Nanovesicles With Mechanically Induced Adjuvanticity for Robust Melanoma Vaccination Toward Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
Rigidity‐tunable nanovesicle (P‐Pm) with mechanically induced adjuvanticity toward tumor‐associated macrophages (TAMs) was designed to engineer R848/gp100 antigen ‐loaded nanovaccine (P@Rg‐Pm), which achieved outstanding anti‐tumor outcomes in both therapeutic and preventive model of B16‐F10 melanoma.
Bangyue Luo, Liyan Qiu
wiley   +1 more source

Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer

open access: yes, 2017
Xiao-li Song,1 Rui-jun Ju,2 Yao Xiao,1 Xin Wang,1 Shuang Liu,1 Min Fu,1 Jing-jing Liu,1 Li-yan Gu,1 Xue-tao Li,1 Lan Cheng1 1School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 2Department of Pharmaceutical Engineering ...
Li X   +9 more
core  

Rocket‐Inspired Sequentially Targeted Nanotherapeutics for Mitochondrial Regulation and Inflammatory Reprogramming in Ischemic Stroke

open access: yesAdvanced Science, EarlyView.
A novel neutrophil‐hitchhiking, rocket‐inspired nanoplatform is developed to cross the blood‐brain barrier for sequential, spatiotemporal drug delivery. By responsive surface transformation in the ischemic penumbra, it precisely targets mitochondria to suppress Drp1‐mediated fission.
He Bai   +17 more
wiley   +1 more source

BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer

open access: yesAdvanced Science, EarlyView.
BCG‐derived HSP70 (Dnak) safely induces central trained immunity via epigenetic, metabolic, and O‐GlcNAcylation reprogramming of bone marrow progenitors, driving tumor‐associated macrophages toward an M1‐like phenotype to suppress prostate cancer. ABSTRACT Trained immunity offers a promising yet clinically challenging strategy for cancer immunotherapy,
Peng Liu   +12 more
wiley   +1 more source

Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation

open access: yesDrug Design, Development and Therapy, 2017
Xiao Zhou, Hui Tao, Kai-Hu Shi Department of Cardiothoracic Surgery, The Second Hospital of Anhui Medical University, Hefei, People’s Republic of China Abstract: The aim of this study was to develop PEGylation liposomes formulations of erlotinib ...
Zhou X, Tao H, Shi KH
doaj  

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

open access: yesAdvanced Science, EarlyView.
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy